Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study
Post-hoc analysis (n=255) found 71.7% of patients had a 50% reduction in seizures and 36.3% had 100% seizure reduction for ≥12 consecutive months during the study. Fatigue, dizziness, somnolence were the most commonly reported adverse effects.
Source:
Epilepsia
SPS commentary:
This is one of two analyses of data from 10 US study sites from an open-label phase 3 study of adjunctive cenobamate published in Epilepsia. The other analysis reviewing use of concomitant antiseizure medicines found 81% had a 50% or more reduction in seizures, with 12% being seizure free, after a median of 30.2 months treatment and 24.6% of patients had discontinued one or more concomitant antiseizure medications completely.
Cenobamate is a sodium channel blocker, with a different binding site to classical sodium channel blocking drugs; it enhances GABAergic transmission by increasing presynaptic GABA release. It is licensed in the UK, but has not yet been launched.